Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2025 | $136.00 | Equal Weight | Barclays |
| 11/21/2025 | Sector Weight | KeyBanc Capital Markets | |
| 7/17/2025 | $155.00 | Outperform → Market Perform | Leerink Partners |
| 6/18/2025 | $160.00 | Buy → Hold | Stifel |
| 12/2/2024 | $215.00 | Outperform | Leerink Partners |
| 7/25/2024 | $220.00 | Buy | BTIG Research |
| 1/12/2024 | $195.00 → $215.00 | Buy | Stifel |
| 12/19/2023 | $230.00 | Buy | Jefferies |
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --
Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well tolerated, including by cats identified with kidney disease at IRIS stage 1, 2 or 31. Portela is also approved in the European Union (EU), and Zoetis anticipates making Portela commercially available in Canada and the EU in 2026. "H
Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. "The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives
8-K - Zoetis Inc. (0001555280) (Filer)
8-K - Zoetis Inc. (0001555280) (Filer)
10-Q - Zoetis Inc. (0001555280) (Filer)
Barclays initiated coverage of Zoetis with a rating of Equal Weight and set a new price target of $136.00
KeyBanc Capital Markets initiated coverage of Zoetis with a rating of Sector Weight
Leerink Partners downgraded Zoetis from Outperform to Market Perform and set a new price target of $155.00
3 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
4 - Zoetis Inc. (0001555280) (Issuer)
For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species. Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar
Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
SC 13G/A - Zoetis Inc. (0001555280) (Subject)
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company's common stock as of the close of business on Tuesday, January 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide --
Underscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth, Profitability and Shareholder Value Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. "The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives
Reports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 9% Organic Operational Growth in Adjusted Net Income for Third Quarter 2025 Reports Adjusted Net Income of $754 Million, or Adjusted Diluted EPS of $1.70, for Third Quarter 2025 Revises Full Year 2025 Revenue Guidance to $9.400 - $9.475 Billion with Organic Operational Revenue Growth of 5.5% to 6.5% Based on Broader Macro Trends and the Operational Environment Narrows Full Year 2025 Guidance for Organic Operational Growth in Adjusted Net Income